| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| LYL273 for Patients With Relapsed or Refractory mCRCNCT05319314 | LYEL | Phase 1, Phase 2 | Recruiting | 2028-06Estimated |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaNCT05320198 | IRON | Phase 1, Phase 2 | Recruiting | 2027-05Estimated |
| Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar LinesNCT05320393 | EOLS | Phase 2 | Completed | 2023-05-22Actual |
| Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaNCT05322473 | MoonLake Immunotherapeutics AG | Phase 2 | Completed | 2023-05-09Actual |
| Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseaseNCT05327803 | ANTX | Phase 2, Phase 3 | Terminated | 2024-12-18Actual |
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)NCT05328102 | XNCR | Phase 2 | Terminated | 2023-02-21Actual |
| A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesNCT05329766 | RCUS | Phase 2 | Completed | 2026-09-07Actual |
| A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)NCT05335122 | OCUL | Phase 2 | Completed | 2024-01-24Actual |
| RNS System LGS Feasibility StudyNCT05339126 | NeuroPace | Phase 2 | Active not recruiting | 2026-11-30Estimated |
| A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)NCT05343455 | Journey Medical Corporation | Phase 3 | Completed | 2023-06-30Actual |
| Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) DeficiencyNCT05345171 | RARE | Phase 3 | Active not recruiting | 2027-09Estimated |
| Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade HemorrhoidsNCT05348200 | CTXR | Phase 2 | Completed | 2023-04-20Actual |
| Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALSNCT05349721 | PTC Therapeutics | Phase 2 | Terminated | 2024-09-26Actual |
| Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPNCT05352893 | Vanda Pharmaceuticals | Phase 3 | Completed | 2023-08-17Actual |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe HypertriglyceridemiaNCT05355402 | IONS | Phase 2 | Completed | 2023-03-22Actual |
| To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing CancersNCT05356741 | VIR | Phase 1, Phase 2 | Recruiting | 2028-04Estimated |
| A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALSNCT05357950 | NRSN | Phase 2 | Completed | 2023-11-02Actual |
| A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PDNCT05357989 | ANVS | Phase 3 | Completed | 2023-12-04Actual |
| 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseNCT05358821 | SUPN | Phase 2 | Completed | 2024-02-29Actual |
| Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular CarcinomaNCT05359861 | CHRS | Phase 2 | Terminated | 2025-06-30Actual |
| Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep DisturbancesNCT05361707 | Vanda Pharmaceuticals | Phase 3 | Unknown | 2025-07Estimated |
| Administration of ARS-1 or Albuterol in Subjects With Persistent AsthmaNCT05363670 | SPRY | Phase 2 | Completed | 2024-02-02Actual |
| Natrunix or Placebo in Combination With Methotrexate in Rheumatoid ArthritisNCT05363891 | XBIT | Phase 2 | Completed | 2024-10-31Actual |
| Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPNCT05366855 | Vanda Pharmaceuticals | Phase 3 | Terminated | 2024-07-12Actual |
| A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaNCT05368285 | Celldex Therapeutics | Phase 2 | Completed | 2023-09-28Actual |
| A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal AndrogensNCT05370521 | Spruce Biosciences | Phase 2 | Terminated | 2023-08-03Actual |
| A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)NCT05371613 | DNLI | Phase 2, Phase 3 | Active not recruiting | 2027-12Estimated |
| Phase 3 Boosting Study for the SARS-CoV-2 rS Variant VaccinesNCT05372588 | Novavax | Phase 3 | Completed | 2022-07-17Actual |
| A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderNCT05376150 | XENE | Phase 2 | Completed | 2023-09-18Actual |
| PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell LymphomaNCT05380635 | Soligenix | Phase 2 | Completed | 2022-08-16Actual |
Trial details
- Registry ID
- NCT05319314
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT05320198
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT05320393
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05322473
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05327803
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05328102
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05329766
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05335122
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05339126
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05343455
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05345171
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05348200
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05349721
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05352893
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05355402
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05356741
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT05357950
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05357989
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05358821
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05359861
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05361707
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05363670
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05363891
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05366855
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05368285
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05370521
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05371613
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05372588
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05376150
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05380635
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.